This trial is active, not recruiting.

Condition esophagogastroduodenoscopy
Sponsor NinePoint Medical
Start date July 2014
End date March 2016
Trial size 1000 participants
Trial identifier NCT02215291, 13_02


This is a prospective, multi-site registry with longitudinal follow up for patients undergoing EGD or endoscopy. The primary objective is to provide a collection of patient NvisionVLE™ procedural data for participating physicians, including, but not limited to, imaging data, clinical utility data, demographics, pathology, treatment, and surveillance.

Up to 1000 patients from up to 20 sites nationwide.

There are no protocol defined follow up visits. Patients will undergo an initial baseline Volumetric Laser Endomicroscopy (VLE) procedure. A patient with a negative screening examination may not require additional screening endoscopies. For patients with established disease, further surveillance endoscopies will vary based on the extent of the disease (e.g. every 3 months, every 6 months, annual), which is based on the following American Society for Gastrointestinal Endoscopy (ASGE) guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. If patients have additional VLE procedures during the enrollment period, associated data will be collected.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
The cohort includes patients undergoing EGD or esophagoscopy for initial diagnosis or initial staging and mapping, surveillance of non-treated disease, and treatment (initial or ongoing) or post-treatment surveillance

Primary Outcomes

Percent of patients with endoscopically visible disease/ suspicious areas as determined by the physician
time frame: Baseline
Percent of patients with VLE visible abnormalities/ suspicious areas as determined by the physician
time frame: Baseline
Percent of patients with histologically confirmed disease and a breakdown of diseases observed
time frame: Baseline
Percent of treated patients with endoscopic and VLE identified areas of retained or persistent abnormalities at the first endoscopic evaluation after treatment
time frame: Baseline
Percent of treated patients undergoing surveillance with endoscopic and VLE areas of recurrent abnormality diagnosed by histology as disease
time frame: Baseline
Percent of patients with abnormalities/ suspicious areas identified by the physician as subsquamous visualized on VLE and not seen on endoscopy
time frame: Baseline

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patients presenting for an endoscopic examination of the esophagus - Ability to provide written, informed consent to participate in the Registry Exclusion Criteria: - Patients for whom use of the NvisionVLE device would be in conflict with the Instructions for Use (IFU)

Additional Information

Principal investigator Michael Smith, MD, MBA
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by NinePoint Medical.